Why insider trading matters?

When insiders buy shares on the open market, this can thus be regarded as a strong endorsement by those that know the company the best -- they are literally betting their own money on the company's future. Insider selling, however, is not necessarily meaningful in any way, as there is a range of reasons for insiders to liquidate (some) of the shares they own.

- Seeking Alpha
Aptinyx Inc. (APTX)
Sector: Healthcare; Industry: Biotechnology

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.


Trade Date Insider Title Buy/Sell #Shares Price Value Option
2020-10-26 Bain Capital Life Sciences Investors, LLC 10%-Owner Buy 3,333,333 $3.00 $9,999,999 No
2020-01-22 Sherman Rachel E. Director Buy 2,174 $4.79 $10,413 No
2020-01-14 Koppel Adam 10%-Owner, Director Buy 3,333,333 $3.00 $9,999,999 No
2020-01-10 ADAMS STREET PARTNERS LLC 10%-Owner Buy 1,000,000 $3.00 $3,000,000 No
2020-01-10 RIEDEL NORBERT G CEO and President Buy 35,000 $3.00 $105,000 No
2020-01-10 HOMBACH ROBERT J. Director Buy 50,000 $3.00 $150,000 No
2020-01-10 Gosebruch Henry O Director Buy 25,000 $3.00 $75,000 No
2020-01-10 ENRIGHT PATRICK G Director Buy 261,667 $3.00 $785,001 No
2019-11-22 HOMBACH ROBERT J. Director Buy 50,000 $3.23 $161,750 No
2019-05-08 Gosebruch Henry O Director Buy 100,000 $3.86 $385,624 No
2019-01-28 Madsen Torsten M. Chief Medical Officer Buy 1,050 $5.27 $5,534 No
2019-01-25 HOMBACH ROBERT J. Director Buy 25,000 $5.53 $138,233 No
2019-01-18 KHANNA ASHISH CFO and CBO Buy 10,000 $5.45 $54,500 No
2018-06-25 New Leaf Venture Management III, L.L.C. 10%-Owner Buy 250,000 $16.00 $4,000,000 Yes
2018-06-25 Frazier Life Sciences VIII, L.P. 10%-Owner Buy 150,000 $16.00 $2,400,000 Yes
2018-06-25 HOMBACH ROBERT J. Director Buy 24,100 $16.00 $385,600 No
2018-06-25 Longitude Capital Partners II, LLC 10%-Owner Buy 150,000 $16.00 $2,400,000 Yes
2018-06-25 Topper James N 10%-Owner, Director Buy 150,000 $16.00 $2,400,000 Yes
2018-06-25 Ratcliffe Liam 10%-Owner, Director Buy 250,000 $16.00 $4,000,000 Yes
2018-06-25 Koppel Adam Director Buy 400,000 $16.00 $6,400,000 Yes
2018-06-25 Gould Terry P 10%-Owner, Director Buy 150,000 $16.00 $2,400,000 Yes
2018-06-25 ENRIGHT PATRICK G Director Buy 150,000 $16.00 $2,400,000 Yes
2018-06-25 GANTZ WILBUR H Director Buy 23,100 $16.00 $369,600 Yes
2018-06-25 MOSKAL JOSEPH R. Chief Scientific Officer Buy 3,000 $16.00 $48,000 Yes
2018-06-25 Madsen Torsten M. Chief Medical Officer Buy 1,000 $16.00 $16,000 Yes
2018-06-25 KIDD ANDREW Chief Commercial Officer Buy 6,700 $16.00 $107,200 Yes
2018-06-25 KHANNA ASHISH CFO and CBO Buy 7,800 $16.00 $124,800 Yes
2018-06-25 RIEDEL NORBERT G CEO and President Buy 2,400 $16.00 $38,400 Yes
2018-06-25 ADAMS STREET PARTNERS LLC 10%-Owner Buy 150,000 $16.00 $2,400,000 Yes

Insider Smart

Carvana Co (CVNA) - One of the best timed insider buying in the crash is from GARCIA ERNEST C. II 10%-owner of CVNA. Bought at 45 and now with a 100%+ profit.

Insider Smart

ROYAL CARIBBEAN CRUISES (RCL) - Thompson Donald, Director of RCL feels safe and made a move. The only insiders bought RCL post crash.